Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Margetuximab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : MacroGenics
Deal Size : $75.0 million
Deal Type : Acquisition
MacroGenics Enters into Agreement with TerSera Therapeutics for The Sale of MARGENZA®
Details : Under the agreement, TerSera will acquire global rights to Margenza (margetuximab) from MacroGenics. It is indicated for the treatment of HER2-positive breast cancer.
Product Name : Margenza
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 22, 2024
Lead Product(s) : Margetuximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : MacroGenics
Deal Size : $75.0 million
Deal Type : Acquisition
Lead Product(s) : Goserelin Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Approves ZOLADEX LA for ER-Positive Breast Cancer in Premenopausal Women
Details : Health Canada has approved a sNDA for ZOLADEX LA (goserelin acetate), GnRH agonist at 10.8mg every 12 weeks for the management of ER+ early breast cancer in pre- and perimenopausal women.
Product Name : Zoladex
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 07, 2024
Lead Product(s) : Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Product Name : Xermelo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2021
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First randomized, double-blind, controlled trial evaluating IV cetirizine versus IV diphenhydramine in the prevention of hypersensitivity infusion reactions. QUZYTTIR is the first and only injectable second-generation H1 antihistamine to be approved by t...
Product Name : Quzyttir
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telotristat
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Lowell Anthony, MD
Deal Size : Inapplicable
Deal Type : Inapplicable
Telotristat With Lutathera in Neuroendocrine Tumors
Details : Telotristat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 10, 2020
Lead Product(s) : Telotristat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Lowell Anthony, MD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Lexicon pharmaceuticals
Deal Size : $224.0 million
Deal Type : Agreement
Lexicon Pharmaceuticals Enters Into Agreement With Tersera Therapeutics For The Sale Of Xermelo
Details : As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients.
Product Name : Xermelo
Product Type : Miscellaneous
Upfront Cash : $159.0 million
July 30, 2020
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Lexicon pharmaceuticals
Deal Size : $224.0 million
Deal Type : Agreement